In another trial reported today in the New England Journal of Medicine, doctors reported that 57% of 82 lung cancer patients with the ALK gene alteration experienced dramatic tumor shrinkage with the Pfizer drug.
FORBES: Pfizer Drug Powers Cancer Treatment Into The DNA Age